457 related articles for article (PubMed ID: 28683775)
1. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
[TBL] [Abstract][Full Text] [Related]
2. Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer.
Shiihara J; Ohyanagi F; Amari H; Toda M; Tahara H; Yuzawa M; Maeda Y; Nomura M; Mizushina Y; Nagai Y; Ohta H; Yamaguchi Y
Thorac Cancer; 2021 Sep; 12(17):2420-2423. PubMed ID: 34324792
[TBL] [Abstract][Full Text] [Related]
3. Sequential Therapy with Crizotinib and Alectinib in ALK-Rearranged Non-Small Cell Lung Cancer-A Multicenter Retrospective Study.
Ito K; Hataji O; Kobayashi H; Fujiwara A; Yoshida M; D'Alessandro-Gabazza CN; Itani H; Tanigawa M; Ikeda T; Fujiwara K; Fujimoto H; Kobayashi T; Gabazza EC; Taguchi O; Yamamoto N
J Thorac Oncol; 2017 Feb; 12(2):390-396. PubMed ID: 27498387
[TBL] [Abstract][Full Text] [Related]
4. Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status.
Tanaka H; Taima K; Morimoto T; Nakamura K; Tanaka Y; Itoga M; Takanashi S; Okumura K
BMC Res Notes; 2016 Mar; 9():173. PubMed ID: 26987388
[TBL] [Abstract][Full Text] [Related]
5. Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.
Hayashi N; Fujita A; Saikai T; Takabatake H; Sotoshiro M; Sekine K; Kawana A
Intern Med; 2018 Mar; 57(5):713-716. PubMed ID: 29151522
[TBL] [Abstract][Full Text] [Related]
6. First line crizotinib in anaplastic lymphoma kinase (ALK) rearranged squamous cell lung cancer.
Mikes RE; Jordan F; Hutarew G; Studnicka M
Lung Cancer; 2015 Dec; 90(3):614-6. PubMed ID: 26519123
[TBL] [Abstract][Full Text] [Related]
7. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
8. Safety of alectinib for the treatment of metastatic ALK-rearranged non-small cell lung cancer.
Zhu V; Ou SH
Expert Opin Drug Saf; 2017 Apr; 16(4):509-514. PubMed ID: 28276856
[TBL] [Abstract][Full Text] [Related]
9. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
Shirasawa M; Kubotaa M; Harada S; Niwa H; Kusuhara S; Kasajima M; Hiyoshi Y; Ishihara M; Igawa S; Masuda N
Lung Cancer; 2016 Sep; 99():66-8. PubMed ID: 27565916
[TBL] [Abstract][Full Text] [Related]
10. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
11. Clinical Efficacy of Alectinib in Patients with
Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Hida T; Yatabe Y
Anticancer Res; 2017 Nov; 37(11):6477-6480. PubMed ID: 29061835
[TBL] [Abstract][Full Text] [Related]
12. ALK-rearranged squamous cell lung carcinoma responding to crizotinib: A missing link in the field of non-small cell lung cancer?
Vergne F; Quéré G; Andrieu-Key S; Descourt R; Quintin-Roué I; Talagas M; De Braekeleer M; Marcorelles P; Uguen A
Lung Cancer; 2016 Jan; 91():67-9. PubMed ID: 26603857
[TBL] [Abstract][Full Text] [Related]
13. Rapid and dramatic response to alectinib in an anaplastic lymphoma kinase rearranged non-small-cell lung cancer patient who is critically ill.
Yoshida T; Hida T; Yatabe Y
Anticancer Drugs; 2016 Jul; 27(6):573-5. PubMed ID: 26938871
[TBL] [Abstract][Full Text] [Related]
14. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
15. ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.
Ou SH; Milliken JC; Azada MC; Miller VA; Ali SM; Klempner SJ
Lung Cancer; 2016 Jan; 91():70-2. PubMed ID: 26464158
[TBL] [Abstract][Full Text] [Related]
16. Case report: continued treatment with alectinib is possible for patients with lung adenocarcinoma with drug-induced interstitial lung disease.
Nitawaki T; Sakata Y; Kawamura K; Ichikado K
BMC Pulm Med; 2017 Dec; 17(1):173. PubMed ID: 29207989
[TBL] [Abstract][Full Text] [Related]
17. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
Yamamoto Y; Okamoto I; Otsubo K; Iwama E; Hamada N; Harada T; Takayama K; Nakanishi Y
Invest New Drugs; 2015 Oct; 33(5):1148-50. PubMed ID: 26334220
[TBL] [Abstract][Full Text] [Related]
18. The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer.
Srinivasamaharaj S; Salame BK; Rios-Perez J; Kloecker G; Perez CA
Expert Rev Anticancer Ther; 2016 Dec; 16(12):1227-1233. PubMed ID: 27744726
[TBL] [Abstract][Full Text] [Related]
19. ALK Rearrangement Positive Lung Adenocarcinoma in Pregnancy Treated With Alectinib: A Case Report.
Gonzalez-Mosquera LF; Rous FA; Rogers A; Smith N; Goyert G; Gadgeel S
Clin Lung Cancer; 2024 Mar; 25(2):e77-e80. PubMed ID: 38057186
[TBL] [Abstract][Full Text] [Related]
20. Alectinib: a review of its use in advanced ALK-rearranged non-small cell lung cancer.
McKeage K
Drugs; 2015 Jan; 75(1):75-82. PubMed ID: 25428710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
